全文获取类型
收费全文 | 126170篇 |
免费 | 10707篇 |
国内免费 | 8171篇 |
专业分类
耳鼻咽喉 | 1020篇 |
儿科学 | 1564篇 |
妇产科学 | 2322篇 |
基础医学 | 14806篇 |
口腔科学 | 2061篇 |
临床医学 | 16426篇 |
内科学 | 20670篇 |
皮肤病学 | 1448篇 |
神经病学 | 6876篇 |
特种医学 | 4297篇 |
外国民族医学 | 70篇 |
外科学 | 13099篇 |
综合类 | 18919篇 |
现状与发展 | 24篇 |
一般理论 | 5篇 |
预防医学 | 7810篇 |
眼科学 | 3653篇 |
药学 | 12790篇 |
115篇 | |
中国医学 | 6038篇 |
肿瘤学 | 11035篇 |
出版年
2024年 | 348篇 |
2023年 | 1827篇 |
2022年 | 4669篇 |
2021年 | 5872篇 |
2020年 | 4223篇 |
2019年 | 4062篇 |
2018年 | 4130篇 |
2017年 | 3690篇 |
2016年 | 3462篇 |
2015年 | 5214篇 |
2014年 | 6535篇 |
2013年 | 6095篇 |
2012年 | 8903篇 |
2011年 | 9763篇 |
2010年 | 5947篇 |
2009年 | 4735篇 |
2008年 | 6511篇 |
2007年 | 6495篇 |
2006年 | 6544篇 |
2005年 | 6481篇 |
2004年 | 4459篇 |
2003年 | 4212篇 |
2002年 | 3561篇 |
2001年 | 3223篇 |
2000年 | 3309篇 |
1999年 | 3448篇 |
1998年 | 2243篇 |
1997年 | 2169篇 |
1996年 | 1564篇 |
1995年 | 1457篇 |
1994年 | 1267篇 |
1993年 | 819篇 |
1992年 | 1227篇 |
1991年 | 1075篇 |
1990年 | 931篇 |
1989年 | 823篇 |
1988年 | 712篇 |
1987年 | 668篇 |
1986年 | 508篇 |
1985年 | 463篇 |
1984年 | 249篇 |
1983年 | 178篇 |
1982年 | 118篇 |
1981年 | 116篇 |
1980年 | 76篇 |
1979年 | 120篇 |
1978年 | 59篇 |
1976年 | 52篇 |
1975年 | 55篇 |
1974年 | 65篇 |
排序方式: 共有10000条查询结果,搜索用时 35 毫秒
1.
2.
3.
4.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
5.
6.
7.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献8.
9.
10.
Yuan-Zhang Tang Bai-Shan Wu Li-Qiang Yang Jian-Ning Yue Liang-Liang He Na Li Jia-Xiang Ni 《Medicine》2015,94(45)
To evaluate the efficacy of computed tomography (CT) guided single radiofrequency thermocoagualtion (RFT) in 1137 patients with idiopathic trigeminal neuralgia after a follow-up period of 11 years, specially focused on duration of pain relief in different branches of trigeminal nerve, side effect, and complications.Retrospective study of patients with idiopathic trigeminal neuralgia treated with a single CT guided RFT procedure between January 2002 and December 2013.The mean follow-up time was 46.14 ± 30.91 months. Immediate postprocedure pain relief was 98.4%. V2 division obtained the best pain relief rate: 91%, 89%, 80%, 72%, 60%, and 54% at 1, 3, 5, 7, 9, and 11 years, respectively. No statistical difference pairwise comparison was in other groups. The complications included masseter muscle weakness, corneitis, diplopia, ptosis, hearing loss, limited mouth opening, and low pressure headache. Masticatory weakness mostly occurred in patients with V3 branch involvement, while Corneitis and Diplopia all in patients with V1 branch involvement. No mortalities observed during or after RFT.All different branches division of trigeminal neuralgia achieved comparable satisfactory curative effect; V2 obtained the best excellent pain relief, after RFT procedure. Facial numbness is inevitable after RFT, which patients who have pain in all 3 trigeminal divisions and patients who desire no facial numbness should be cautious. Masticatory weakness is mainly related with V3 injured, while Corneitis and Diplopia in patients with V1 injured by RFT. 相似文献